Loading…
Fierce Drug Dev Forum 2019 has ended
avatar for Emily Minkow

Emily Minkow

PREVAIL THERAPEUTICS
Chief Business Officer
Emily Minkow is the Chief Business Officer of Prevail Therapeutics. Prior to Prevail, Emily held positions of increasing responsibility at Celgene Corporation for seven years, most recently as Executive Director of Business Development. There, she led deal evaluation and execution across a broad range of licensing transactions, mergers and acquisitions, and collaborations, with a focus on immunology, oncology and neurodegeneration. Emily was Director of Global Marketing during Celgene’s worldwide launch of Otezla for psoriasis and psoriatic arthritis, providing leadership in strategic planning and brand management. At Celgene she was also the Integration Team Leader following the company’s $7.2 billion acquisition of Receptos, and Principal to the company’s Chairman and CEO. Earlier in her career, Emily was a consultant for Frankel Group, where she advised biotech and pharmaceutical companies on clinical and commercial strategy.Emily holds an MBA from Harvard Business School and a Bachelor’s degree in public and international policy from Princeton University.